Showing 771-780 of 4944 results for "".
Unplugged: Cutting-Edge Aesthetic Medicine
https://practicaldermatology.com/conferences/asds-2022-annual-meeting/unplugged-cutting-edge-aesthetic-medicine/20142/Jeanine Downie, MD shares pearls from her presentation in the Unplugged session she co-chaired with José Montes, MD. She discusses some of the latest tightening devices for the face, neck, and body, including EmFace, Zaffiro, and Sofwave. Plus, she reviews topics presented by colleagues throughout tThe Roots of Dermatology
https://practicaldermatology.com/topics/practice-management/the-roots-of-dermatology/18355/The roots of dermatology run deep. The specialty formed in Europe, but Americans soon took a leading role in shaping the future of the field. This first of four episodes explores the early days of the specialty and takes stock of dermatology today.Clinical Conversations: MOA of JAK Inhibitors in Dermatology
https://practicaldermatology.com/series/jak-inhibitors-in-practice/clinical-conversations-moa-of-jak-inhibitors-in-dermatology/20096/JAK inhibitors have a range of potential applications in clinical dermatology. In the first video of this series, Brad Glick, DO and Raj Chovatiya, MD explain the mechanism of action of JAK inhibitors and explain how they may be used topically or systemically to treat skin diseases like atopic dermaChallenging Cases
https://practicaldermatology.com/conferences/maui-derm-2022/challenging-cases/20054/Seemal R. Desai, MD was part of the Challenging Cases session on everything from new infectious diseases to challenging surgical and aesthetic complications. He says dermatologists play an important role in saving and transforming patients' lives.DermWire TV: Adbry Approved; Syringoma Option; Confusion over Vaccines and Injectables
https://practicaldermatology.com/series/dermwire-tv/dermwire-tv-adbry-approved-syringoma-option-confusion-over-vaccines-and-injectables/20041/Adbry (tralokinumab) from Leo Pharma is the newest biologic approved for moderate to severe atopic dermatitis in adults and is the first IL-13 blocker approved in the US. Pulse Bioscience’s nano-pulse stimulation (NPS) technology shows potential for the treatment of syringoma in a feasibility studyRethink How You Market Your Practice During the Holidays
https://practicaldermatology.com/topics/practice-management/rethink-how-you-market-your-practice-during-the-holidays/23607/Winter can be the “gift that keeps on giving”—if you know how to leverage the season.An Update on Neuromodulators and Fillers
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/an-update-on-neuromodulators-and-fillers/19983/Suneel Chilukuri, MD discusses daxibotulinumtoxinA and its potential for longer lasting results. He also reviews newly available fillers and specific options for various areas of the face. Plus, he talks about low-cost options and how he’s using devices like SkinPen.DermWireTV: Cosentyx for Kids; Anifrolumab for SLE, Tremfya in PsA at EULAR
https://practicaldermatology.com/topics/psoriasis/dermwiretv-cosentyx-for-kids-anifrolumab-for-sle-tremfya-in-psa-at-eular/19948/FDA has approved Cosentyx (secukinumab) from Novartis for patients as young as six years old. The 2nd Annual San Diego Dermatology Symposium kicks off as a live Virtual Experience next Friday. A post-hoc analysis of pooled data from the TULIP Phase 3 clinical trials shows that anifrolumab improvesThe Secret Sauce of Business Success During COVID-19
https://practicaldermatology.com/topics/practice-management/the-secret-sauce-of-business-success-during-covid-19/23424/How to run an efficient and successful business for the long run.Troubleshooting teledermatology
https://practicaldermatology.com/topics/practice-management/troubleshooting-teledermatology/19854/Doctors and patients alike praise the ability of technology to enable virtual care, but this rapid transition has not been entirely trouble-free. In this video from Ekwa Marketing, we look at some of the most common problems, and how you might be able to avoid or solve them.